Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors.
Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. Gasparre G, et al. Among authors: tallini g. Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6. doi: 10.1073/pnas.0703056104. Epub 2007 May 15. Proc Natl Acad Sci U S A. 2007. PMID: 17517629 Free PMC article.
The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization.
Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Morra I, Ciccarelli E, Melcarne A, Bartoletti-Stella A, Salfi N, Tallini G, Martinuzzi A, Carelli V, Attimonelli M, Rugolo M, Romeo G, Gasparre G. Porcelli AM, et al. Among authors: tallini g. Hum Mol Genet. 2010 Mar 15;19(6):1019-32. doi: 10.1093/hmg/ddp566. Epub 2009 Dec 22. Hum Mol Genet. 2010. PMID: 20028790
Molecular features of thyroid oncocytic tumors.
Gasparre G, Bonora E, Tallini G, Romeo G. Gasparre G, et al. Among authors: tallini g. Mol Cell Endocrinol. 2010 May 28;321(1):67-76. doi: 10.1016/j.mce.2010.02.022. Epub 2010 Feb 23. Mol Cell Endocrinol. 2010. PMID: 20184940 Review.
Clinical experience with gefitinib: an update.
Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L. Cappuzzo F, et al. Among authors: tallini g. Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45. doi: 10.1016/j.critrevonc.2005.08.008. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531062 Review.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. Among authors: tallini g. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. Xing M, et al. Among authors: tallini g. J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20. J Clin Oncol. 2015. PMID: 25332244 Free PMC article.
293 results